Company Overview of Research Corporation Technologies Inc.
Research Corporation Technologies Inc. is a venture capital firm specializing in incubations, start up, and early-stage companies. It is a technology development company that typically invests in new technology platforms in life sciences, biomedical, preclinical and clinical-stage therapeutics, devices, drugs, and diagnostics, and biotech tools for gene expression and protein production. Within preclinical and clinical-stage drugs, diagnostics and devices, the firm focuses on cancer, pain and metabolic diseases; cardiovascular diseases; back-of-the-eye and immune disorders; and infectious diseases and diagnostics. Within cancer, the firm focuses on anticancer agents, agents to treat cancer-...
5210 East Williams Circle
Tucson, AZ 85711-4410
Founded in 1987
Key Executives for Research Corporation Technologies Inc.
President of Biotechnologies and Director
President of Medical Devices
Director of Administration
Compensation as of Fiscal Year 2014.
Research Corporation Technologies Inc. Key Developments
Research Corporation Technologies and BioGrammatics Announce their Partnership to Commercialize and Distribute Pichia GlycoSwitch
Jun 4 13
Research Corporation Technologies and BioGrammatics Inc. announced their partnership to commercialize and distribute Pichia GlycoSwitch (R) -- a new expression system to modify the glycosylation of recombinant proteins in the yeast Pichia pastoris. Pichia GlycoSwitch(R) adds to the advantages of using Pichia pastoris as a host for the production of recombinant proteins with increased flexibility over protein glycosylation (the addition of sugars to a protein of interest). Under the partnership, BioGrammatics will provide expression system kits and services; RCT will oversee commercial licensing programs.
Lucigen Corporation and Research Corporation Technologies Announce Partnership and Launch Endotoxin-free CleanColi™ Expression System
May 1 13
Lucigen Corporation and Research Corporation Technologies (RCT) announced a partnership to commercialize and distribute the CleanColi™ Expression System, the first Escherichia coli (E. coli)-based recombinant system that lacks unwanted endotoxin. Lucigen will produce and sell kits containing CleanColi™ competent cells and provide contract research services for the CleanColi™ Expression System. Lucigen simultaneously announces the release of a CleanColi™ competent cell line enabling the production of proteins virtually free of endotoxin contamination, thereby minimizing purification and allowing faster and more accurate screening of biological targets for drug discovery research. Under the partnership, RCT will be responsible for the CleanColi™ commercial licensing programs. Drug discovery researchers are increasingly turning to biologics as the source for new therapeutics, utilizing the incredible diversity of proteins in order to find new treatments for disease. To synthesize and manipulate these proteins, researchers normally insert genes coding for the desired protein into mammalian, yeast, or bacterial cells. The common bacteria E. coli is a widely used system for expression of recombinant proteins, but this method has the disadvantage that, without time-consuming and expensive cleanup, it produces contaminating endotoxin that kills human cells. Failure to remove endotoxin from the final product can result in false or misleading results, potentially causing a researcher to improperly reject a promising drug candidate. Lucigen and RCT have developed the CleanColi™ competent cell strain for protein expression. This new strain has a genetically modified lipopolysaccharide (LPS) that does not cause an endotoxic response in human cells. By producing proteins without contaminating endotoxin, researchers can increase productivity by reducing the time, cost, and loss of product associated with endotoxin removal. More important, cell-based assays can be performed without concern that LPS (endotoxin) contamination could be masking promising results. Researchers can accelerate drug discovery research and ensure the most accurate results possible. Additional cell lines for plasmid production and phage display are also planned for release, creating a complete system for scientists to study a large variety of biologic compounds for therapeutic applications.
Research Corporation Technologies Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013
Dec 19 12
Research Corporation Technologies Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013 . Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions